Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:EVFMNYSE:LCINASDAQ:ORGSNASDAQ:PPBT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$7.34-0.3%$6.52$2.65▼$9.01$201.33M1.49454,348 shs131,079 shsEVFMEvofem Biosciences$0.03+62.5%$0.03$0.01▼$4.38$840K-1.191.18 million shs2.05 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsORGSOrgenesis$0.85$0.56$0.25▼$1.50$27.13M1.0485,839 shs15,432 shsPPBTPurple Biotech$0.62$0.72$0.53▼$2.16$15.42M0.97118,253 shs70,410 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.27%-2.52%-2.65%+42.80%+164.03%EVFMEvofem Biosciences+42.86%+64.56%+23.22%-57.72%-99.01%LCILannett0.00%0.00%0.00%0.00%-56.06%ORGSOrgenesis-0.13%-5.56%+35.14%+69.32%-35.11%PPBTPurple Biotech-0.50%-4.67%-13.01%-24.40%-64.77%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.1309 of 5 stars3.51.00.04.52.82.50.6EVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/AORGSOrgenesis1.118 of 5 stars0.03.00.04.41.91.70.6PPBTPurple Biotech3.0705 of 5 stars3.55.00.00.04.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$38.00417.71% UpsideEVFMEvofem Biosciences2.00HoldN/AN/ALCILannettN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/APPBTPurple Biotech3.00Buy$9.001,351.61% UpsideCurrent Analyst RatingsLatest ABEO, PPBT, LCI, EVFM, and ORGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/27/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M57.36N/AN/A$0.60 per share12.23EVFMEvofem Biosciences$16.84M0.07N/AN/A($62.94) per share0.00LCILannett$340.58M0.00N/AN/A($23.34) per share0.00ORGSOrgenesis$27.75M0.98N/AN/A$1.14 per share0.75PPBTPurple BiotechN/AN/AN/AN/A$1.36 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)EVFMEvofem Biosciences-$76.70MN/A0.00∞N/A344.82%-77.85%237.94%4/26/2024 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/AORGSOrgenesis-$14.89M-$0.91N/A∞N/A-91.25%-107.27%-35.64%4/2/2024 (Estimated)PPBTPurple Biotech-$19.88M-$0.92N/AN/AN/AN/A-57.40%-49.02%5/21/2024 (Estimated)Latest ABEO, PPBT, LCI, EVFM, and ORGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/2024Q4 2023PPBTPurple Biotech-$0.17-$0.32-$0.15-$0.45N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15EVFMEvofem BiosciencesN/A0.170.13LCILannettN/A2.231.39ORGSOrgenesis1.480.610.61PPBTPurple BiotechN/A2.202.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%EVFMEvofem Biosciences0.22%LCILannett40.28%ORGSOrgenesis22.56%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%EVFMEvofem Biosciences0.21%LCILannett13.12%ORGSOrgenesis7.14%PPBTPurple Biotech2.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableEVFMEvofem Biosciences3545.94 million45.84 millionNot OptionableLCILannett81010.77 million9.35 millionOptionableORGSOrgenesis16731.88 million29.60 millionOptionablePPBTPurple Biotech2025.24 million24.49 millionOptionableABEO, PPBT, LCI, EVFM, and ORGS HeadlinesSourceHeadlinePurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyfinanznachrichten.de - March 14 at 12:40 PMPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyglobenewswire.com - March 14 at 7:30 AMHere's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisherzacks.com - March 13 at 10:56 AMPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023investorplace.com - March 5 at 11:52 PMPurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 5 at 1:22 PMPurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 5 at 7:55 AMPurple Biotech ADR (PPBT) Earnings Dates & Reportsinvesting.com - March 3 at 6:09 PMBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN Treatmentmarkets.businessinsider.com - February 27 at 10:57 PMPurple Biotech Ltd ADRmorningstar.com - February 27 at 5:56 PMPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024globenewswire.com - February 27 at 7:00 AMPurple Biotech Ltd. ADRwsj.com - February 22 at 2:20 PMPurple Biotech Ltd ADR PPBTmorningstar.com - February 15 at 12:30 AMPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trialfinance.yahoo.com - February 13 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)markets.businessinsider.com - February 1 at 5:47 PMPurple Biotech stock climbs 9% on Phase 2 study updatemsn.com - February 1 at 12:47 PMPurple Biotech Reaches Recommended Phase 2 Dose for NT219finance.yahoo.com - February 1 at 7:47 AMPurple Biotech Appoints Dr. Yael Margolin to its Board of Directorsfinance.yahoo.com - December 20 at 9:18 AMPurple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinanznachrichten.de - December 14 at 10:30 AMPurple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinance.yahoo.com - December 14 at 10:30 AMEncouraging Early Data For Biotech's Cancer Therapiesinvestorideas.com - November 22 at 12:58 PMPromising Clinical Trial Results and Accelerated Enrollment Boost Purple Biotech’s Buy Ratingmarkets.businessinsider.com - November 22 at 7:58 AMPurple Biotech Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 21 at 10:25 AMPurple Biotech Fortifies NT219 Patent Protectionfinance.yahoo.com - November 2 at 10:41 AMPurple Biotech Announces Closing of $5 Million Registered Direct Offeringfinance.yahoo.com - October 19 at 5:53 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.OrgenesisNASDAQ:ORGSOrgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.Purple BiotechNASDAQ:PPBTPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.